CT1812 treatment for early Alzheimer's disease
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months
A daily medicine called CT1812 is given to people with early Alzheimer's disease to see whether it protects brain connections and helps thinking over 18 months.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cognition Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11135309 on NIH RePORTER |
What this research studies
If you join, you would be randomly assigned to take CT1812 or a placebo each day without knowing which one you receive, and the study runs for 18 months. Doctors will monitor your memory and thinking with regular cognitive tests, check safety, and collect blood and cerebrospinal fluid samples to measure toxic amyloid oligomers and synaptic markers. The drug is designed to displace harmful amyloid-beta oligomers from synapses and move them into the CSF, a mechanism that showed biomarker changes in short-term testing. Visits will include clinic assessments, lab tests, and procedures such as lumbar puncture as required by the protocol.
Who could benefit from this research
Good fit: Ideal candidates are adults with early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia due to AD) who meet medical entry criteria and can attend regular clinic visits and procedures like lumbar puncture.
Not a fit: People with advanced Alzheimer's, other major neurological illnesses, or those unable or unwilling to undergo spinal taps or frequent visits may not be eligible or likely to benefit.
Why it matters
Potential benefit: If successful, CT1812 could reduce synapse damage from toxic amyloid oligomers and slow cognitive decline in people with early Alzheimer's disease.
How similar studies have performed: Short-term studies of CT1812 showed promising changes in CSF and blood biomarkers and reduction of synaptic damage markers, but clinical improvement in cognition has not yet been proven and the approach remains relatively novel.
Where this research is happening
Pittsburgh, United States
- Cognition Therapeutics, INC. — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Caggiano, Anthony O — Cognition Therapeutics, INC.
- Study coordinator: Caggiano, Anthony O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.